FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Sanofi launches new trial for dengue fever

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!

  • Subscribe
  • Email
  • Print
  • Contact Author
  • Reprint

Sanofi-Pasteur has launched a clinical trial in Thailand to test a tetravalent vaccine for dengue fever, the world's second most common tropical disease in children. Adding to the urgency for the program is evidence that dengue fever has been spreading into new parts of the world.

"Large scale pediatric studies are instrumental for the development of a safe and efficacious dengue vaccine to protect against a disease that primarily affects children," said Dr. Pratap Singhasivanon, dean of the Faculty of Tropical Medicine, Mahidol University. "We are happy to contribute to an important milestone with the actual start of an efficacy study in Ratchaburi."

Out of some 230 new infections each year, about one percent develop dengue hemorrhagic fever. Sanofi CEO Chris Viehbacher said recently that increasing the company's work in vaccines would be a primary focus in the years to come.

- check out Sanofi release

ALSO: Sanofi is also sponsoring a Phase II clinical study of a vaccine against Clostridium difficile, which is among the most common causes of hospital-acquired infection in Europe and North America. Release

Related Articles:
Sanofi to plow $6B into vaccines
Booming vaccine market swells Sanofi's revenue

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about Dengue fever   Sanofi-Aventis   clostridium difficile